View the historical price chart for CGC to analyze trends and spot opportunities. Use our interactive chart to compare past performance and make informed decisions.
No, CGC stock may not be the best buy in 2025 based on our comprehensive analysis.
Comprehensive analysis of whether CGC stock is a good investment in 2025, including growth drivers, valuation metrics, risk factors, and analyst recommendations.
CGC presents a mixed investment profile for 2025. The company shows strong growth drivers including healthcare sector momentum, though small-cap with higher growth potential and volatility.
Analyst sentiment is mixed with 1 buy ratings vs 3 sell ratings.
Investors should weigh the growth potential against the identified risks, particularly high debt-to-equity ratio of 67.04, and consider their own risk tolerance and investment timeline.
Based on our comprehensive analysis of CGC's financial metrics, growth prospects, valuation, analyst sentiment, and risk factors, we recommend a SELL. This recommendation considers the company's current fundamentals, market position, and future growth potential while accounting for identified risks and market conditions.
Based on revenue growth analysis and market trends, cgc stock is projected to reach $2.02 by 2030, representing a 35.6% increase from the current price of $1.49.
Get detailed analyst targets, key factors, and comprehensive forecast analysis
Analyze financial statements and market position
Review price charts and technical indicators
Evaluate market and company-specific risks
Healthcare
Drug Manufacturers - Specialty & Generic
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It oper...
Make buy/hold/sell decision with price targets
Get detailed step-by-step analysis, risk assessment, and investment strategies
1 Hershey Drive, Smiths Falls, ON K7A 0A8
Canada
Get detailed executive information, governance metrics, and comprehensive corporate data